CarproMax INJECTION

Country: Ástralía

Tungumál: enska

Heimild: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Virkt innihaldsefni:

CARPROFEN

Fáanlegur frá:

ABBEY LABORATORIES PTY LTD

Lyfjaform:

PARENTERAL LIQUID/SOLUTION/SUSPENSION

Samsetning:

CARPROFEN ANTI-INFLAMMATORY-NONSTEROIDAL Active 50.0 mg/ml

Einingar í pakka:

20mL

Tegund:

VM - Veterinary Medicine

Lækningarsvæði:

ANALGESIC+MUSCULOSKELETAL

Vörulýsing:

Poison schedule: 4; Withholding period: MEAT WITH HOLDING PERIOD (HORSE): DO NOT USE less than 28 days before slaughter for human consumption.; Host/pest details: CAT: [ANALGESIC, ANTI-INFLAMMATORY AGENT, NON STEROIDAL]; DOG: [ANALGESIC, ANTI-INFLAMMATORY AGENT, NON STEROIDAL]; HORSE: [ANALGESIC, ANTI-INFLAMMATORY AGENT, NON STEROIDAL]

Leyfisstaða:

Registered

Leyfisdagur:

2023-07-01

Upplýsingar fylgiseðill

CarproMax INJECTION
91746/133351
Product Name:
APVMA Approval No:
Label Name:
CarproMax INJECTION
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
50 mg/mL CARPROFEN
Claims:
CarproMax injection is a non-steroidal, anti-inflammatory formulation
with analgesic
action. It is indicated as an aid in the alleviation of pain and
inflammation associated with
musculoskeletal disorders and for anti-inflammatory treatment after
surgery in the horse.
In the dog and cat, it is indicated for the control of post-operative
pain and inflammation
following orthopaedic and soft tissue (including intra-ocular)
surgery.
Net Contents:
20 mL
Directions for Use:
Restraints:
DO NOT administer by intramuscular injection.
DO NOT exceed the recommended dose or duration of treatment.
DO NOT administer other NSAID’s concurrently or within 24 hours of
each other. Some
NSAID’s may be highly bound to plasma proteins and compete with
other highly bound
drugs, which can lead to toxic effects.
DO NOT use in any animal less than 6 weeks of age, or in aged animals.
Contraindications:
Contraindicated in animals suffering from cardiac, hepatic, or renal
disease, or where
there is evidence of a blood dyscrasia or hypersensitivity to the
product. Avoid use in any
dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of increased
renal toxicity. RLP APPROVED
Precautions:
Where there is a possibility of gastro-intestinal ulceration or
bleeding, use may involve
additional risk. If such a use cannot be avoided, animals may require
a reduced dosage
and careful clinical management.
Concurrent administration of potential nephrotoxic drugs should be
avoided. In the absence
of any specific studies in pregnant target animals, such use is not
indicated.
NSAID’s can cause inhibition of phagocytosis and hence, in the
treatment of inflammatory
conditions associated with bacterial infection, appropriate concurrent
antimicrobial therapy
should be instigated.
Side Effe